Ugh, ugh, and ugh. Quite a few stocks got hit hard this week, but few like three especially unlucky health-care stocks. April Fools' Day is over, but shareholders of this week's big losers probably still feel like someone is pulling a prank on them.

One of this week's ugliest stocks felt the repercussions of having to halt a clinical study because of potential safety concerns. Another is a former high-flying IPO stock that continues to see the wind abandoning its sails. The third felt the agony of potential defeat being snatched from the jaws of victory by a Supreme Court decision.

Which stocks made this week's list of horrendous performers? Check out the following slideshow to find out.


Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Momenta Pharmaceuticals and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.